目的 分析奧沙利鉑聯(lián)合替吉奧治療晚期結(jié)直腸癌的療效。方法 以2013年1月-2015年8月陜西省商洛市第二人民醫(yī)院收治的90例結(jié)腸、直腸癌患者為研究對(duì)象，根據(jù)住病歷順序號(hào)分為觀察組和對(duì)照組，每組45例。對(duì)照組采用奧沙利鉑聯(lián)合氟尿嘧啶的化療方案，4周為1個(gè)治療周期；觀察組采用奧沙利鉑聯(lián)合替吉奧的化療方案，21 d為1個(gè)治療周期。比較兩組的療效、不良反應(yīng)、生活質(zhì)量及1年生存率。結(jié)果 治療后，觀察組的總緩解率高于對(duì)照組，疾病控制率低于對(duì)照組，但兩組間比較，差異均無(wú)統(tǒng)計(jì)學(xué)意義。治療期間，兩組Ⅰ度和Ⅱ度不良反應(yīng)發(fā)生率比較，差異均無(wú)統(tǒng)計(jì)學(xué)意義；Ⅲ度和Ⅳ度的不良反應(yīng)中，觀察組的胃腸道反應(yīng)、肝功能受損、白細(xì)胞減少的發(fā)生率顯著低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；其他各項(xiàng)間比較，差異均無(wú)統(tǒng)計(jì)學(xué)意義。兩組間SF-36量表中各項(xiàng)評(píng)分差值間無(wú)統(tǒng)計(jì)學(xué)意義。觀察組治療后1年生存率為46.67%（21/45），對(duì)照組治療后1年生存率為42.22%（19/45），兩組1年生存率比較，差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 奧沙利鉑聯(lián)合替吉奧與奧沙利鉑聯(lián)合氟尿嘧啶化療方案治療晚期結(jié)直腸癌的療效以及對(duì)患者生活質(zhì)量的影響效果相當(dāng)，但奧沙利鉑聯(lián)合替吉奧的胃腸道、肝及骨髓抑制的不良反應(yīng)情況優(yōu)于奧沙利鉑聯(lián)合氟尿嘧啶化療方案。

Objective To analyze the curative effect of oxaliplatin combined with S-1 in the treatment of advanced colorectal cancer. Methods Totally 90 cases of patients with advanced colorectal cancer in Shangluo No.2 Provincial People's Hospital from January 2013 to August 2015 were divided into observation group and control group, 45 cases in each group. Patients in control group were treated with oxaliplatin combined with fluorouracil, 4 weeks for one cycle of treatment, and patients in observation group were treated with oxaliplatin combined with S-1, 21 d for one cycle. The curative effects, adverse reactions, life quality, and one year survival rate were compared between two groups. Results After treatment, the total remission rate of observation group was higher than that of control group, and the disease control rate was lower than that of the control group, but there was no significant difference between the two groups. During the treatment, there were no significant differences in I degree and II degree adverse reactions between two groups; But the adverse reactions of level III and level IV of gastrointestinal reaction, liver function damage, reduce the incidence of white blood cells in observation group were significantly lower than that of control group (P<0.05). There was no significant difference between the two groups in the SF-36 scale scores. The one year survival rate of observation group was (21/45), and the survival rate of the control group after treatment was 42.22% (19/45) in the control group, and there was no significant difference between the two groups in the one year survival rate. Conclusion Compared with oxaliplatin combined with fluorouracil, oxaliplatin combined with S-1 has equivalent efficacy and life quality, but the adverse reactions in gastrointestinal tract, liver, and marrow were better.